Search results for "10179 Institute of Medical Microbiology"

showing 2 items of 2 documents

A Library-Based Screening Strategy for the Identification of DARPins as Ligands for Receptor-Targeted AAV and Lentiviral Vectors

2021

Delivering genes selectively to the therapeutically relevant cell type is among the prime goals of vector development. Here, we present a high-throughput selection and screening process that identifies designed ankyrin repeat proteins (DARPins) optimally suited for receptor-targeted gene delivery using adeno-associated viral (AAV) and lentiviral (LV) vectors. In particular, the process includes expression, purification, and in situ biotinylation of the extracellular domains of target receptors as Fc fusion proteins in mammalian cells and the selection of high-affinity binders by ribosome display from DARPin libraries each covering more than 1012 variants. This way, DARPins specific for the …

0301 basic medicinelcsh:QH426-470610 Medicine & healthComputational biologyQH426-470BiologyGene deliveryArticleViral vector03 medical and health sciences0302 clinical medicine1311 GeneticsLV10019 Department of Biochemistry1312 Molecular BiologyGeneticsVector (molecular biology)lcsh:QH573-671Molecular Biology030304 developmental biology0303 health sciencesQH573-671lcsh:Cytology10179 Institute of Medical Microbiologyribosome displayCorrectionAAVFusion proteinlcsh:GeneticsCD105NKp46DARPin030104 developmental biologyGluA4DARPin1313 Molecular Medicine030220 oncology & carcinogenesisBiotinylationRibosome displayreceptor-targeted viral vectors570 Life sciences; biologyMolecular MedicineAnkyrin repeatCytologyMolecular Therapy - Methods & Clinical Development
researchProduct

TBVAC2020: Advancing Tuberculosis Vaccines from Discovery to Clinical Development

2017

International audience; TBVAC2020 is a research project supported by the Horizon 2020 program of the European Commission (EC). It aims at the discovery and development of novel tuberculosis (TB) vaccines from preclinical research projects to early clinical assessment. The project builds on previous collaborations from 1998 onwards funded through the EC framework programs FP5, FP6, and FP7. It has succeeded in attracting new partners from outstanding laboratories from all over the world, now totaling 40 institutions. Next to the development of novel vaccines, TB biomarker development is also considered an important asset to facilitate rational vaccine selection and development. In addition, …

TuberculosiImmunologybacille Calmette–Guérin610 Medicine & healthReview[SDV.MHEP.PSR]Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseasesTuberculosis; Bacille Calmette-Guérin; Vaccination; Biomarker; Clinical trial; Portfolio management; Discovery[SDV.BC.IC]Life Sciences [q-bio]/Cellular Biology/Cell Behavior [q-bio.CB]Immunology and AllergyBacille Calmette-Guérinbacille Calmette-Guérinbacille Calmette-Guerin2403 Immunology10179 Institute of Medical MicrobiologyBacille Calmette-Guérin; Biomarker; Clinical trial; Discovery; Portfolio management; Tuberculosis; Vaccination; Immunology and Allergy; Immunologyclinical trialvaccination[SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriology[SDV.GEN.GH]Life Sciences [q-bio]/Genetics/Human geneticstuberculosis2723 Immunology and Allergy570 Life sciences; biologybiomarkerportfolio managementdiscovery
researchProduct